Impax Asset Management Group plc Lowers Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Impax Asset Management Group plc lessened its holdings in Repligen Co. (NASDAQ:RGEN) by 0.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,051,939 shares of the biotechnology company’s stock after selling 6,230 shares during the period. Impax Asset Management Group plc owned 1.88% of Repligen worth $150,267,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of RGEN. Blue Trust Inc. boosted its stake in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares during the period. Resources Management Corp CT ADV bought a new position in Repligen in the 3rd quarter worth approximately $37,000. Quarry LP grew its holdings in Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares in the last quarter. UMB Bank n.a. raised its position in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares during the last quarter. Finally, Global Retirement Partners LLC raised its position in shares of Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 129 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group raised their target price on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday. Canaccord Genuity Group began coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $180.00 target price on shares of Repligen in a research report on Friday. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 price target for the company. Finally, Royal Bank of Canada lifted their price objective on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Stock Performance

NASDAQ:RGEN opened at $158.99 on Monday. The firm has a market capitalization of $8.91 billion, a PE ratio of -311.75, a PEG ratio of 4.54 and a beta of 0.99. The stock’s fifty day moving average is $155.22 and its 200 day moving average is $148.59. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $203.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. On average, sell-side analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.